The Dx Reboot: Decentralizing Care from Labs to Living Room
The shift in the at-home diagnostics paradigm is quickly transitioning from a product-centric model to an integrated, intelligent, and connected ecosystem. For industry participants, it is a new channel full of possibilities and opportunities. There is a fundamental redefinition of value for all fields, from neurodiagnostics to viral diseases. The “Accuracy Curve” is far beyond analytical specificity and sensitivity within the four walls of the lab. It now extends to patients’ homes, public health databases, and clinicians’ EHRs.
What Does it Mean for OEMs?
The strategic imperative for OEMs is two-faced. On one hand, they must address the decentralization dilemma, while on the other hand, they need to reduce the diagnostic divide proactively. The market lead wouldn’t belong to the best product manufacturers, but rather to the successful orchestrators of impact across the value chain.
More on this subject:
Looking Forward to Meeting You at:
Webinar: Gain a clearer understanding of the current state of Value-based Healthcare (VBHC), the reasons behind its slow adoption, and business scenarios that will likely emerge as VBHC scales, featuring our medtech experts, Arpit Sharma and Sandhya Saraswat.
Register now at: Driving Impact in Value-based Care
[newsletter_cta]